FLGT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Fulgent Genetics Inc (FLGT) does not present a strong buying opportunity for a beginner investor with a long-term strategy at this time. The technical indicators are mixed, with bearish moving averages and neutral RSI. Options data indicates bearish sentiment with a high put-call volume ratio. Recent news highlights potential legal issues and underperformance in financials, which overshadow the positive acquisition news. Analysts have lowered price targets, and hedge funds are selling. Given the lack of strong positive catalysts and the current uncertainties, holding off on investment is advisable.
The technical indicators show mixed signals. The MACD is positive and expanding, suggesting potential upward momentum. However, the RSI is neutral at 50.679, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels are at 15.602 and 16.034, while support levels are at 14.204 and 13.772. The stock is trading near resistance, which could limit immediate upside potential.
Fulgent Genetics recently completed the acquisition of Bako Diagnostics and StrataDx for $56.9 million, which could enhance its market position in pathology and drive future revenue growth.
The company is under investigation for potential securities violations following a decline in financial performance. Additionally, hedge funds have significantly increased their selling activity (up 169.46% last quarter). The company's Q4 financials showed a net income loss and a drop in gross margin, raising concerns about profitability.
In Q4 2025, revenue increased by 9.34% YoY to $83.34 million. However, net income was -$23.42 million, though it improved by 297.72% YoY. EPS also improved to -0.76, up 300% YoY. Gross margin dropped to 36.67%, down 6.41% YoY, indicating declining efficiency.
UBS recently lowered its price target for FLGT from $35 to $22 while maintaining a Buy rating. This reflects reduced optimism about the stock's near-term potential.
